Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / LXRX - Lexicon Pharmaceuticals enters into $150M loan facility for potential sotagliflozin launch

LXRX - Lexicon Pharmaceuticals enters into $150M loan facility for potential sotagliflozin launch

Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals (NASDAQ:LXRX) has entered into a $150M loan facility with Oxford Finance to provide commercial preparations and support the potential launch of sotagliflozin in heart failure. The loan facility consists of four tranches. The first three are for $25M each, while the fourth is $50M. Sotagliflozin is approved in the European Union as an adjunct to insulin therapy in adults with type 1 diabetes. In late February, Lexicon (LXRX) withdrew in New Drug Application for sotagliflozin in the U.S. to correct a technical issue.

For further details see:

Lexicon Pharmaceuticals enters into $150M loan facility for potential sotagliflozin launch
Stock Information
Company Name: Lexicon Pharmaceuticals Inc.
Stock Symbol: LXRX
Market: NASDAQ
Website: lexpharma.com
Menu
LXRX LXRX Quote LXRX Short LXRX News LXRX Articles LXRX Message Board
Get LXRX Alerts

News, Short Squeeze, Breakout and More Instantly...